180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, will be participating in A.G.P.’s Virtual Biotech Conference. The conference is scheduled for Nov. 30–Dec. 1, 2022. According to the announcement, ATNF president and CEO Dr. James Woody will present during the event. His presentation will include a business and scientific overview of 180 Life Sciences. In addition, Woody will be available for one-on-one and group meetings throughout the two-day virtual gathering.
To view the event, visit https://ibn.fm/OUJUT
To view the full press release, visit https://ibn.fm/X7C82
About 180 Life Sciences Corp.
180 Life Sciences is a clinical-stage biotechnology company driving groundbreaking studies into clinical programs that are seeking to address major unmet medical needs. The company’s primary platform is a novel program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). For more information about the company, visit www.180LifeSciences.com.
NOTE TO INVESTORS: The latest news and updates relating to ATNF are available in the company’s newsroom at https://ibn.fm/ATNF
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.